RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma
C. Nunes, L. Depestel, L. M. Mus, K. M. Keller, L. Delhaye, A. Louwagie, M. Rishfi, E. M. Dolman, V. Olexiouk, C. Bartenhagen, F. Devloed, E. Sanders, A. Eggermont, J. Van Laere, E. De Smet, , F. Speleman
This study identifies RRM2 as a therapeutic target in high-risk neuroblastoma, showing that combined RRM2 and CHK1 inhibition synergistically reduces tumor growth.
bioRxiv · Nov 25, 2020 · PreprintCancer Biology